tbuckley/cabot-search huggingface dataset:
MB-26 * TARGETING MEDULLOBLASTOMA WITH A NEW SMALL-MOLECULE DRUG THAT INHIBITS MYC MEDIATED TRANSLATION
Authors: B. Foreman, I. Alimova, P. Harris, I. Balakrishnan, E. Prince, N. Foreman, R. Vibhakar, S. Venkataraman
Journal: Neuro-Oncology (2015)

Medulloblastoma is the most common pediatric brain tumor.Four molecular subgroups have been identified.Group 3 medulloblastomas are characterized by high Myc amplification and have a particularly poor prognosis, further complicated by the fact that MYC has proven very difficult to target due to the lack of clear binding ligands.In this study we evaluated the effect of a new small-molecule drug, ON 013105, in Myc driven medulloblastoma cell growth and cell death.The drug, ON 013105, a novel benzyl styryl sulfone kinase inhibitor has been shown to inhibit Myc mediated translation, cyclin D and eventually decreases tumor cell proliferation in a mouse model of mantle cell lymphoma.In our studies with high Myc expressing medulloblastoma cells, ON 013105 demonstrates an ability to reduce cell proliferation, cell survival, colony formation, and cell self-renewal capacity.Interestingly, in high Myc medulloblastoma cells, we found that ON 013105 inhibits cMyc expression in addition to cyclin D1 inhibition.Combining ON 013105 with JQ1, another small-molecule drug which inhibits cMyc expression by inhibiting BRD4, showed synergistic decrease in tumor cell proliferation.Our study suggests that ON 013105 either alone or in combination with JQ1 can be potential therapeutic agents to target high MYC medulloblastoma.
Abstract 57: Inhibition of human melanoma proliferation by combination treatment with ODC inhibitor and mTOR inhibitor
Authors: Eddy C. Hsueh, Yanping Zhang, Guangyong Peng
Journal: Cancer Research (2010)

Abstract Recent reports have demonstrated that polyamine synthesis is critical for tumor cell growth. Furthermore, mTOR was also shown to be critical for tumor cell growth. We hypothesized that inhibition of key polyamine synthesis enzyme, ornithine decarboxylase (ODC), and mTOR would have growth inhibitory effect on human melanoma cells. ODC expression was evaluated in human melanoma and human melanoma cell lines by Western blot using polyclonal goat anti-ODC and quantitative real-time PCR using TaqMan Gene Expression Assay Applied Biosystems). The siRNA duplexes targeting ODC and a scrambled control siRNA were designed and synthesized (Santa Cruz, CA) and transient transfections were performed. Cell proliferation assay was performed using Cell Titer Blue cell proliferation assay according to the manufacturer's protocol. The cells were treated with or without various concentrations of DFMO or rapamycin or combination then incubated up to 96 hours. For comparison between groups, the Student's t test were used and p&amp;lt;0.05 was considered to be statistically significant. Over-expression of ODC was observed in human melanoma cells compared with tumor asssociated fibroblasts as well as human melanoma cells. Over-expression of ODC was observed in six of the ten human melanoma cell lines on Western blot analysis and RT-PCR analysis. Dose-dependent growth inhibition of human melanoma cells were observed following DFMO treatment (p&amp;lt;0.05) in melanoma cell lines with over expression of ODC and correlated with suppression of ODC expression levels. Grow inhibition was also observed folllowing Rapamycin treatment in the melanoma cell lines. Treatment with ODC-siRNA also resulted in significant growth inhibition of melanoma cell lines. Effects of DFMO induced growth inhibition of melanoma cells were further enhanced with combined treatment with rapamycin. Overexpression of ODC was observed in human melanoma cells. Inhibition of polyamine synthesis and mTOR can have significant growth inhibitory effects on human melanoma. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 57.
Lack of Increased FDG Uptake in the Lacrimal and Salivary Glands in Patients With Sarcoidosis and Potential Underlying Mechanism
Authors: Hunbo Shim, Junghyun Joo, Hyung Jin Choi, Hyewon Hyun, Victor H. Gerbaudo, Chun K. Kim
Journal: Clinical Nuclear Medicine (2016)

Increased 67Ga uptake in the mediastinal/hilar lymph nodes ("lambda") and in the lacrimal/parotid/submandibular glands ("panda") often coexists in patients with sarcoidosis (Sarc-Pts). However, we observed that increased lacrimal/salivary uptake is uncommon on 18F-FDG PET/CT (FDG-panda) in many Sarc-Pts who showed increased mediastinal/hilar uptake (FDG-lambda). We evaluated parotid and lacrimal FDG activity in Sarc-Pts who showed FDG-lambda in comparison with a control patient group and attempted to find underlying mechanisms to explain the discrepancy between FDG and Ga uptake in these organs.Parotid FDG activity (FDG-P) was assessed visually using a 0- to 3-point scale (0 being = or minimally > background, and 3 > liver) and quantitatively using SUVmean in 52 confirmed Sarc-Pts with FDG-lambda (lambda group) as well as in 52 non-Sarc-Pts (control group). Lacrimal FDG activity (FDG-L) was assessed visually (0 being = or minimally > subcutaneous tissue, and 1 clearly > subcutaneous tissue).There was no significant difference in the parotid SUVmean between lambda (1.88 ± 0.65) and control (1.76 ± 0.62) groups (P = 0.333). Also, there was no difference in visually graded FDG-P between the 2 groups (P = 0.257). None of the patients in all groups showed apparently abnormal (grade 1) FDG-L.Increased FDG-L/FDG-P is rare in Sarc-Pts demonstrating FDG-lambda, which is strikingly different from the clinical experience as well as the reported data on Ga scintigraphy. Discrepancy in various cytokine levels between lacrimal samples and intrathoracic lesions in Sarc-Pts reported in the literature appears to correlate well with variable Ga and FDG uptake in the lacrimal gland and intrathoracic lesions.
Clinical Picture of a Case of Diabetes With Mitochondrial tRNA Mutation at Position 3271
Authors: Yoshihiko Suzuki, Katsunori Tsukuda, Yoshihito Atsumi, Yuichi Goto, Kazuhiro Hosokawa, Takayuki Asahina, Ikuya Nonaka, Kempei Matsuoka, Yositomo Oka
Journal: Diabetes Care (1996)
Association of β-Blocker Treatment With Adverse Outcomes in Hypertensive Patients Undergoing Noncardiac Surgery—Reply
Authors: Mads E. Jørgensen, Mark A. Hlatky, Charlotte Andersson
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Endoscopic ultrasound-guided therapy of a rectal Dieulafoy lesion
Authors: J. Vila, M. Pérez-Miranda, M. Basterra, M. Gómez, I. Fernández-Urién, F. Jiménez
Journal: Endoscopy (2014)

A 68-year-old man with stage IV renal cell adenocarcinoma was admitted for severe lower gastrointestinal bleeding and hemodynamic instability. After blood transfusion, colonoscopy revealed fresh blood in the rectum and sigmoid colon but no apparent lesions. At 4 days after admission, the patient experienced another episode of severe bleeding. A repeat colonoscopy showed active pulsatile bleeding from an exposed vessel without mucosal ulceration, consistent with a Dieulafoy lesion located 3 cm above the anal verge. An endoscopically administered epinephrine injection (1 : 10 000) stopped the bleeding. After 5 days, recurrence of bleeding was noted from the treated vessel but it ceased with appropriate placement of two hemoclips and another epinephrine injection. However, in spite of this endoscopic treatment, 4 days later the patient had re-bleeding. Endoscopic ultrasound (EUS)-guided vascular treatment was planned prior to considering surgical treatment ([Video 1]). The ultrasonographic view showed a persistently wide-caliber vessel, that is, without any sign of tapering, coursing directly toward the mucosal surface ([Fig. 1]) with arterial flow ([Fig. 2]). Under EUS guidance, the rectal wall was punctured the needle tip directed toward the vessel ([Fig. 3]) and 6 mL of 2 % polidocanol was injected, with cessation of bleeding ([Fig. 4]). Subsequently, the patient did not experience any new bleeding episodes and was discharged, however, 2 months later he passed away following progression of his oncologic disease.
CB-11 * DIVERSE ROLES FOR RhoA AND RhoC IN GLIOBLASTOMA
Authors: A. Kwiatkowska, V. Paulino, Z. Dong, J. Loftus, J. Kloss, R. Ruggieri, N. Tran, M. Symons
Journal: Neuro-Oncology (2014)

A number of Rho family members have been shown to control tumor cell proliferation, survival and invasion. Rhophilin, an effector of both RhoA and RhoC, is amplified in glioblastoma and its expression strongly correlates with decreased patient survival. Importantly, rhophilin 2 has recently also been shown to be a critical driver gene of the mesenchymal phenotype in human glioblastoma. However, the cellular functions of RhoA and RhoC in glioblastoma largely remain to be characterized. Here we show that depletion of RhoA, but not RhoC, significantly inhibits glioblastoma cell proliferation. Conversely, depletion of RhoC, but not RhoA, significantly inhibits glioblastoma cell invasion into ex vivo brain slices. In line with this, depletion of RhoC, but not RhoA, also inhibits nuclear squeezing through a 3 mm pore size filter. In addition, we found that depletion of either RhoA or RhoC inhibit glioblastoma cell survival in clonogenic assays. Thus, RhoA and RhoC differentially regulate distinct aspects of the malignant behavior of glioblastoma. We also have identified PDZ-RhoGEF as a critical activator of both RhoA and RhoC in glioblastoma cells, as depletion of this guanine nucleotide exchange factor strongly diminishes serum-stimulated activation of both GTPases. In addition, consistent with the results of depleting either RhoA or RhoC, we showed that depletion of PDZ-RhoGEF, significantly inhibits glioblastoma cell proliferation, invasion and clonogenicity. We also showed that depletion of PDZ-RhoGEF significantly enhances mouse survival in a patient-derived xenograft model.
Abstract 4315: Extracellular signal regulated kinase 5 inpathogenesis of malignant mesothelioma.
Authors: Arti Shukla, Jill Miller, Christopher Cason, Mutlay Sayan, Maximilian MacPherson, Stacie Beuschel, Brooke Mossman
Journal: Cancer Research (2013)

Abstract Malignant mesothelioma (MM) is a neoplastic disease of the pleural, peritoneal or pericardial cavity. Currently, there is no therapy for MM as it is resistant to most of the common chemotherapies and therefore, there is a need for new treatment strategies. In the present study we demonstrated that ERK5 is important in MM tumor growth and can potentially be targeted in combination with the chemotherapeutic drugs for more effective treatment. Human MM cell lines exhibit constitutive activation of ERK5. Addition of doxorubicin to these MM cell lines resulted in further activation of ERK5. ERK5 silencing by small hairpin RNA (shERK5) increased DOX-induced cell death and DOX retention in human MM cells. In addition, shERK5 MM lines exhibited both attenuated colony formation on soft agar and invasion of MM cells in vitro. Most importantly, injection of shERK5 MM cell lines into SCID mice showed significant reduction in tumor growth using both subcutaneous and intraperitoneal models. Finally, use of doxorubicin and cisplatin in combination with ERK5 inhibition showed further reduction in tumor weight and volume in the IP model of tumor growth, proving our hypothesis that ERK5 inhibition in combination with chemotherapeutic drugs is a beneficial strategy for combination therapy in MM patients. This work is supported by Mesothelioma Applied Research Foundation (AS), NIEHS-RO1ES021110 (AS) and T32 ES07122 (BM) grants. Citation Format: Arti Shukla, Jill Miller, Christopher Cason, Mutlay Sayan, Maximilian MacPherson, Stacie Beuschel, Brooke Mossman. Extracellular signal regulated kinase 5 inpathogenesis of malignant mesothelioma. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4315. doi:10.1158/1538-7445.AM2013-4315
Amelioration of Chemotherapy-Induced Thrombocytopenia by GM-CSF: Apparent Dose and Schedule Dependency
Authors: J. H. EDMONSON, H. J. LONG, J. A. JEFFRIES, J. C. BUCKNER, G. COLON-OTERO, T. R. FITCH
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article Amelioration of Chemotherapy-Induced Thrombocytopenia by GM-CSF: Apparent Dose and Schedule Dependency Get access JOHN H. EDMONSON, JOHN H. EDMONSON Mayo ClinicRochester, MN Search for other works by this author on: Oxford Academic PubMed Google Scholar HARRY J. LONG, HARRY J. LONG Mayo ClinicRochester, MN Search for other works by this author on: Oxford Academic PubMed Google Scholar JOHN A. JEFFRIES, JOHN A. JEFFRIES Mayo ClinicRochester, MN Search for other works by this author on: Oxford Academic PubMed Google Scholar JAN C. BUCKNER, JAN C. BUCKNER Mayo ClinicRochester, MN Search for other works by this author on: Oxford Academic PubMed Google Scholar GERARDO COLON-OTERO, GERARDO COLON-OTERO Mayo ClinicJacksonville, FL Search for other works by this author on: Oxford Academic PubMed Google Scholar TOM R. FITCH TOM R. FITCH Mayo ClinicScottsdale, AZ Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 19, 4 October 1989, Pages 1510–1512, https://doi.org/10.1093/jnci/81.19.1510-a Published: 04 October 1989
Evaluation prospective de la performance diagnostique de l'aspiration de bile avant et après brossage biliaire en association au brossage biliaire par CPRE dans le diagnostic des sténoses biliaires malignes
Authors: G Roth, P Bichard, H Roth, M Fior-Gozlan, J Auroux, I Bricault, C Letoublon, V Leroy, T Decaens
Journal: Endoscopy (2015)

Le diagnostic cytologique obtenu par cytobrossage biliaire des sténoses suspectes est considéré comme spécifique mais très peu sensible. Peu d'études cliniques proposent des techniques visant à améliorer les performances diagnostiques de cette cytologie biliaire.
Ga-67 Scintigraphy in Patients with Breast Lymphoma
Authors: YOSHIHIRO NISHIYAMA, YUKA YAMAMOTO, KOTARO FUKUNAGA, KATASHI SATOH, MOTOOMI OHKAWA
Journal: Clinical Nuclear Medicine (2002)

The authors studied the utility of Ga-67 citrate scintigraphy in patients with breast lymphoma.Seven patients with histologically proved breast lymphoma were examined. In three patients, both breasts were involved, and all patients had rapidly growing breast masses. Planar and SPECT images were obtained 72 hours after injection of Ga-67.Ga-67 scintigraphy showed intense accumulation in all lymphomas. SPECT images provided better contrast than did planar images. In one of the seven patients, the axilla and mediastinum were also involved. In six of the seven patients, Ga-67 scintigraphy was also performed after treatment and showed the disappearance of Ga-67 accumulation. In one patient with local recurrence and lung involvement, abnormal accumulation was depicted on follow-up Ga-67 scintigraphy.Ga-67 scintigraphy was helpful to confirm the diagnosis and the systemic extent of lymphoma and to evaluate the therapeutic effect during follow-up in patients with breast lymphoma.
The Incidental Discovery of Follicular Thyroid Cancer with In-111 Pentetreotide Scintigraphy in a Patient with Carcinoid Tumor of the Lung
Authors: GIUSEPPE VILLA, GIOVANNI B. RATTO, MARCO CARLETTO, HAMED ROUHANIFAR, ARNOLDO PICCARDO, LUIGI TOMMASI, VANIA ALTRINETTI, CARLO MEREU, GIULIANO MARIANI
Journal: Clinical Nuclear Medicine (2003)

VILLA, GIUSEPPE M.D.; RATTO, GIOVANNI B. M.D.; CARLETTO, MARCO M.D.; ROUHANIFAR, HAMED M.D.; PICCARDO, ARNOLDO M.D.; TOMMASI, LUIGI M.D.; ALTRINETTI, VANIA M.D.; MEREU, CARLO M.D.; MARIANI, GIULIANO M.D. Author Information
Late phase II study of S-1 in patients with taxane resistant breast cancer
Authors: M. Hino, T. Saeki, Y. Sato, M. Sano
Journal: Journal of Clinical Oncology (2004)

745 Background: S-1 is a novel oral anticancer agent, contains tegafur (FT: prodrug of 5-fluorouracil), 5-chloro-2,4-dihydroxypyridine (CDHP: dehydropyrimidine dehydrogenase inhibitor), and potassium oxonate (Oxo: orotate phosphoribosyl transferase inhibitor) at a molar ratio of FT:CDHP:Oxo = 1:0.4:1. We conducted this study to evaluate the efficacy and safety of S-1, in patients (pts) with taxane resistant breast cancer (BC). Methods: Eligibility criteria were as follows: informed consent was obtained, age >=20 to <75, had histologicaly confirmed BC, had metastatic BC, had received one or two prior chemotherapeutic regimens one of which had to have contained paclitaxel or docetaxel, progression or relapse was confirmed within 6 months after taxane treatment, has one or more measurable region, has adequate organ function, PS 0–2, life expectancy more then 3 months. S-1 was given orally at 40mg/m2 b.i.d. for 28 consecutive days followed by 14 days rest period and repeated in 42 day cycles. The cycles were continued until disease progressed. Results: Between November 2001 and April 2003, 56 pts were registered on the trial, and 55 pts received treatment with S-1. All pts had received taxane treatment, and 40 (72.7%) of 55 pts had received anthracycline containing chemotherapy. Response was evaluated based on RECIST criteria at independent review committee. Twelve (21.8%) of the 55 pts (95% CI 11.8 – 35.0%) were confirmed partial responders and there was no complete responder. The median overall survival period was 470 days (Follow-up is being continued). The grade (G) 4 treatment-related adverse event (AE) wasn't observed. The most common G3 treatment-related AEs were neutoropenia (10.9%), leucopenia (9.1%), diarrhea (5.5%) and anorexia (5.5%). There was no G3–4 hand-foot syndrome, even G2 was 5.5%. Almost all AEs were manageable with brief drug interruption or dose reduction. Conclusions: S-1 is an active drug in the treatment of taxane resistant BC and has favorable toxicity profiles. No significant financial relationships to disclose.
AB0643 Ultrasounography assessment of non-deforming lupus arthropathy
Authors: C.A. Guillen Astete, C.C. Macía Villa, A.L. Boteanu, W.A. Sifuentes Giraldo, A. Zea Mendoza
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Lupus arthropathy has different compromise levels, not always progressive, that includes asymptomatic forms, deforming, erosive or even resorptive arthropathy. Until now, the ultrasonography (US) is useful to assess inflammatory status in patients with chronic or episodic arthritis. Recent studies have shown that inflammatory activity is demonstrable by US in other types of arthropathy. <h3>Objectives</h3> To perform an US assessment of non-deforming forms of SLE arthropathy and its relationship with other clinical findings. <h3>Methods</h3> 76 medical records of SLE patients without deforming arthropathy were revised. Epidemiological, clinical and laboratory data were collected. A complementary medical interview were performed to all patients in order to review clinical and historical data. US protocol applied to all patients included both carpal joint (dorsal and ventral), 2nd and 3rd metacarpophalangeal (MCP) of both hands, 2nd and 3rd flexor tendons of both hands at its passage through the MCP joints. US studies were perform to assess the existence or absence of synovitis, effusion, tendinosis and power doppler signal (PDS). For the statistical analysis, x<sup>2</sup> and T student tests were used where appropriate. <h3>Results</h3> We identified three groups of joint involvement according to clinical data: (1) Asymptomatic patients n=15, (2) patients with intermittent or continuous arthralgias n=40, and (3) patients with arthritis n=21. Times of disease from diagnosis were different in the three groups. A 66,67% of patients from group 1 was diagnosed with 3 or more analytical criteria and 33,3% with 3 or more clinical criteria. The inverse proportion was found in group 2 and 3. All those comparissons were statistically significant. The clinical response to NSAID, hydroxycloroquine, metotrexate and glucocorticoids were similar among the groups. Synovial effusion and PDS were present in 33 and 40% respectively in group 1. Synovial effusion was present in 15% and 61,9% of group 2 and 3 respectively. <h3>Conclusions</h3> (1) We have demonstrated ecographic inflammatory activity in SLE patients that in our cohort reaches 40% of the asymptomatic patients. These results widely surpass other series results probably because we have considered positive any PDS level of intensity and not only the clinically significant. (2) In patients without clinical arthritis, there is enough ecographic evidence of it in more than one third of patients. (3) There is an association between SLE diagnoses based in clinical criteria with inflammatory, clinical and ecographic joints manifestations. <h3>Disclosure of Interest</h3> None Declared
Cells, Research, and Informed Consent
Authors: LEO UZYCH
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Cells, Research, and Informed Consent Get access LEO UZYCH LEO UZYCH Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 5, 6 March 1991, Page 368, https://doi.org/10.1093/jnci/83.5.368 Published: 06 March 1991
Image Fusion of Magnetic Resonance and F-18 FDG Positron Emission Tomography Using a Dual-Head Camera in Coincidence Mode To Determine the Viability of an Embryonic Rhabdomyosarcoma Residual Mass After Proton Radiation and Chemotherapy
Authors: JOHN JOHANNA ZAKNUN, FRANZ-MARTIN FINK, STEPHAN FELBER, DANIELA ZAKNUN
Journal: Clinical Nuclear Medicine (2001)

ZAKNUN, JOHN JOHANNA M.D.; FINK, FRANZ-MARTIN M.D.; FELBER, STEPHAN M.D.; ZAKNUN, DANIELA M.D. Author Information